Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.56 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11440863 | 0.89 | MAPT (0.53) | ALDH1A1MAPTHPGDHTTHSP90AA1 | |
| SCHEMBL11442308 | 0.82 | MAPT (0.55) | ALDH1A1MAPTHPGDHTTHSP90AA1 | |
| SCHEMBL3766073 | 0.81 | ALDH1A1 (0.54) | ALDH1A1MAPTHPGDHTTHSP90AA1 | |
| SCHEMBL1038187 | 0.81 | ALDH1A1 (0.54) | ALDH1A1MAPTHPGDHTTHSP90AA1 | |
| SCHEMBL11436375 | 0.81 | ALDH1A1 (0.58) | ALDH1A1MAPTHPGDHTTHSP90AA1 | |
| SCHEMBL3160988 | 0.81 | HDAC3 (0.63) | ALDH1A1MAPTHPGDHTTHSP90AA1 | |
| SCHEMBL14415407 | 0.79 | ALDH1A1 (0.53) | ALDH1A1MAPTHPGDHTTHSP90AA1 | |
| SCHEMBL23924461 | 0.79 | PLOD2 (0.54) | ALDH1A1MAPTHPGDHTTHSP90AA1 | |
| SCHEMBL3765733 | 0.79 | MAPT (0.56) | ALDH1A1MAPTHPGDHTTHSP90AA1 | |
| SCHEMBL3973753 | 0.79 | ALDH1A1 (0.52) | ALDH1A1MAPTHPGDHTTHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023033890-A1 | NITROGEN-CONTAINING COMPOUNDS AS ADDITIVES FOR SILICON-BASED LI-ION BATTERIES | ENEVATE CORPORATION (US) | 2023-03-09 | — | — | WO | claimed |
| CN-110204507-B | Process for producing 2-aryl-4-alkylthiazole compound | 浙江大学 | 2021-03-02 | — | — | CN | claimed |
| US-12030875-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| EP-3846793-B1 | EIF4E INHIBITORS AND USES THEREOF | PIC THERAPEUTICS INC (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023033890-A1 | NITROGEN-CONTAINING COMPOUNDS AS ADDITIVES FOR SILICON-BASED LI-ION BATTERIES | ENEVATE CORPORATION (US) | 2023-03-09 | — | — | WO | disclosed |
| US-11552334-B1 | Nitrogen-containing compounds as additives for silicon-based Li-ion batteries | ENEVATE CORPORATION (US) | 2023-01-10 | — | — | US | disclosed |
| US-11552334-B1 | Nitrogen-containing compounds as additives for silicon-based Li-ion batteries | ENEVATE CORPORATION (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220089587-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2022-03-24 | — | — | US | disclosed |
| CN-109776352-B | Preparation method of alpha-azido arone derivative | 宁波大学 | 2021-09-03 | — | — | CN | disclosed |
| CN-113164419-A | EIF4E inhibitors and uses thereof | 皮克医疗公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3846793-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| EP-0446010-A1 | Imidazole derivatives and antiepileptics comprising said imidazole derivatives as effective ingredients | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1991-09-11 | — | — | EP | disclosed |
| EP-0092391-A2 | Novel piperidine derivatives and pharmaceutical compositions containing same | KYOWA HAKKO KOGYO CO., LTD (JP) | 1983-10-26 | — | — | EP | disclosed |
| US-4371734-A | Preparation of thiazole derivatives | BASF AKTIENGESELLSCHAFT (DE) | 1983-02-01 | — | — | US | disclosed |
| US-4250090-A | COLORFASTNESS; WETFASTNESS; ACID AZO DYES | BASF AKTIENGESELLSCHAFT (DE) | 1981-02-10 | — | — | US | disclosed |
| EP-0003501-B1 | PROCESS FOR THE PREPARATION OF THIAZOLE DERIVATIVES | BASF Aktiengesellschaft (DE) | 1981-01-07 | — | — | EP | disclosed |
| US-4230723-A | Combating plant bacteria with acylhalogenomethyl thiocyanates | BAYER AKTIENGESELLSCHAFT (DE) | 1980-10-28 | — | — | US | disclosed |
| US-4204867-A | THIAZOLE OR IMIDAZOLE FOUR EQUILVALENT COUPLERS | AGFA-GEVAERT, A.G. (DE) | 1980-05-27 | — | — | US | disclosed |
| EP-0005763-A1 | Agents for combating bacterial contamination of plants, their use and preparation | BAYER AG (DE) | 1979-12-12 | — | — | EP | disclosed |
| EP-0003501-A1 | Process for the preparation of thiazole derivatives | BASF Aktiengesellschaft (DE) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030875-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | ALDH1A1 4467/4885MAPT 2395/4885HPGD 4252/4885 |
| US-20220089587-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EEF2K | ALDH1A1 4053/4885MAPT 2522/4885HPGD 4334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.